

This document is an English-translated version of an attachment of notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Voriconazole

June 11, 2024

Therapeutic category

Antibiotic preparations acting mainly on mold

Non-proprietary name

Voriconazole

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision						
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Rifampicin, rifabutin, efavirenz, ritonavir, lopinavir/ritonavir, nirmatrelvir/ritonavir, carbamazepine, barbitol, phenobarbital, pimozide, quinidine, ivabradine, ergot alkaloids (ergotamine/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, ergometrine, methylergometrine), triazolam, ticagrelor, asunaprevir, lomitapide, blonanserin, suvorexant, rivaroxaban, riociguat, azelnidipine, olmesartan medoxomil/azelnidipine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], anamorelin, lurasidone, isavuconazonium</p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <p>(NA)</p>	<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving the following drugs: Rifampicin, rifabutin, efavirenz, ritonavir, lopinavir/ritonavir, nirmatrelvir/ritonavir, carbamazepine, barbitol, phenobarbital, pimozide, quinidine, ivabradine, ergot alkaloids (ergotamine/anhydrous caffeine/isopropylantipyrine, dihydroergotamine, ergometrine, methylergometrine), triazolam, ticagrelor, asunaprevir, lomitapide, blonanserin, suvorexant, rivaroxaban, riociguat, azelnidipine, olmesartan medoxomil/azelnidipine, venetoclax [during its dose escalation phase for relapsed or refractory chronic lymphocytic leukemia (including small lymphocytic lymphoma)], anamorelin, lurasidone, isavuconazonium, <u>finerenone</u></p> <p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p> <table><tr><th>Drugs</th><th>Signs, symptoms, and treatment</th><th>Mechanism/risk factors</th></tr><tr><td><u>Finerenone</u></td><td><u>The blood concentration of finerenone may rise and the effect of finerenone may be enhanced by co-</u></td><td><u>Voriconazole inhibits the metabolizing enzyme of finerenone (CYP3A4).</u></td></tr></table>	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	<u>Finerenone</u>	<u>The blood concentration of finerenone may rise and the effect of finerenone may be enhanced by co-</u>	<u>Voriconazole inhibits the metabolizing enzyme of finerenone (CYP3A4).</u>
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors					
<u>Finerenone</u>	<u>The blood concentration of finerenone may rise and the effect of finerenone may be enhanced by co-</u>	<u>Voriconazole inhibits the metabolizing enzyme of finerenone (CYP3A4).</u>					

		administration with voriconazole.		
--	--	--------------------------------------	--	--

N/A: Not Applicable. No corresponding language is included in the current PRECAUTIONS.